Keytruda for Lung Cancer: Cost, Treatment, Survival Rate, and Side Effects
2025-09-09
•
143 views
Keytruda (pembrolizumab) is a breakthrough immunotherapy for lung cancer that helps the immune system recognize and attack cancer cells. Unlike chemotherapy, Keytruda targets the PD-1/PD-L1 pathway, improving survival rates in patients with non-small cell lung cancer (NSCLC) and certain cases of small cell lung cancer (SCLC). This guide explains how Keytruda works, its cost, side effects, FDA approval, alternatives, and what patients can expect from treatment.
Read More
